How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,345 results for

Prostate Cancer Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Canadian Urological Association (CUA) -Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC)

Canadian Urological Association (CUA) -Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC) CUAJ • October 2019 • Volume 13, Issue 10 © 2019 Canadian Urological Association 307 Cite as: Can Urol Assoc J 2019;13(10):307-14. http://dx.doi.org/10.5489/cuaj.6136 Published online June 25, 2019 MEDLINE search of the English language and conference proceedings were used to produce the present document. Wherever Level 1 evidence is lacking (...) , the guideline attempts to provide expert opinion to aid in the management of patients. Levels of evidence and grades of recommendation employ the International Consultation on Urologic Disease (ICUD)/ WHO modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels

2019 Canadian Urological Association

8. Remote monitoring or self-management for surveillance or follow up of prostate cancer

Remote monitoring or self-management for surveillance or follow up of prostate cancer Remote monitoring of prostate cancer - Health Technology Wales > Remote monitoring of prostate cancer Remote monitoring of prostate cancer Topic Status Incomplete Remote monitoring or self-management for surveillance or follow up of prostate cancer. Summary Health Technology Wales researchers searched for evidence on different methods of prostate remote monitoring/self-management. Although a range of evidence

2019 Health Technology Wales

9. A self-help diet and physical activity intervention with dietetic support for weight management in men treated for prostate cancer: pilot study of the Prostate Cancer Weight Management (PRO-MAN) randomised controlled trial. (PubMed)

A self-help diet and physical activity intervention with dietetic support for weight management in men treated for prostate cancer: pilot study of the Prostate Cancer Weight Management (PRO-MAN) randomised controlled trial. Overweight and obesity may increase risk of disease progression in men with prostate cancer, but there have been few studies of weight loss interventions in this patient group. In this study overweight or obese men treated for prostate cancer were randomised to a self-help

2019 The British journal of nutrition Controlled trial quality: uncertain

10. Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management

Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management Guidelines & Advice (...) Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management english Version: 2 ID: 17-3 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: J. Chin, J. Srigley, L.A. Mayhew, R.B. Rumble, C. Crossley, A. Hunter, N. Fleshner, B. Bora, R. McLeod, S. McNair, B. Langer, A. Evans, Prostate Cancer Surgery and Pathology Expert Panel Guideline Objective The objective of this document is to provide

2017 Cancer Care Ontario

11. Management of locally advanced and metastatic prostate cancer

Management of locally advanced and metastatic prostate cancer Management of locally advanced and metastatic prostate cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate (...) cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Management of locally advanced and metastatic prostate cancer Contents Download Clinical questions: Androgen deprivation therapy (ADT) Radiotherapy Radiotherapy and androgen deprivation therapy (ADT) Surgery Surgery plus androgen deprivation therapy Pathologic T3/T4 disease post radical surgery (Patients with extra capsular extension, seminal vesicle involvement or positive surgical margins) Node-positive

2018 Cancer Council Australia

12. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia (BPH) Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors (...) Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019) Published 2018, Amended 2019 The goal of this revised guideline is to provide a useful reference on the effective evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic

2019 American Urological Association

13. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms 1 Purpose Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society (...) . In the management of bothersome LUTS, it is important that healthcare providers recognize the complex dynamics of the bladder, bladder neck, prostate, and urethra, in addition to the fact that symptoms may result from interactions of these organs as well as with the central nervous system or other systemic diseases (e.g., metabolic syndrome, congestive heart failure). Despite the more prevalent (and often first line) use of medical therapy for men suffering from LUTS attributed to BPH, there still remain

2019 American Urological Association

14. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. (PubMed)

Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country.Six key sections were chosen: (1) high-risk localized and locally advanced (...) of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes.Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world

Full Text available with Trip Pro

2019 BJU international

15. Large ten-year trial on treatment of localised prostate cancer will aid management decisions

Large ten-year trial on treatment of localised prostate cancer will aid management decisions Large ten-year trial on treatment of localised prostate cancer will aid management decisions Discover Portal Discover Portal Large ten-year trial on treatment of localised prostate cancer will aid management decisions Published on 15 September 2016 doi: New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical surgery or radiotherapy (...) , alongside the fact that many localised cancers (confined to the prostate) may not require detection or treatment. Management of localised prostate cancer is controversial because it’s difficult to predict which cancers will behave aggressively. Most will be slow-growing and unlikely to cause many symptoms or affect life-expectancy. Therefore, radical treatments such as surgery or radiotherapy which can have significant side effects may not be necessary, but adopting a “wait and see” policy risks cancer

2019 NIHR Dissemination Centre

16. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management Clinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (CG175) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 45Contents Contents Introduction 5 Drug

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

17. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. (PubMed)

Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. To evaluate the effect of adding multiparametric magnetic resonance imaging (mpMRI) to pre-surgical planning on surgical decision making for the management of high-risk prostate cancer (HRPC).A survey was designed to query multiple centers on surgical decisions of 41 consecutive HRPC cases seen from 2012 to 2015. HRPC was defined by the National Comprehensive Cancer Center Network (...) to extended lymph node dissection in 17%.Although mpMRI is not integrated in guidelines for preoperative planning in HRPC, its use may impact surgical planning, cancer control, and quality of life.

2019 Prostate cancer and prostatic diseases

18. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared (...) Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status

2019 Health Technology Wales

19. How can hot flushes in men being treated for prostate cancer be managed?

How can hot flushes in men being treated for prostate cancer be managed? How can hot flushes in men being treated for prostate cancer be managed? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 1st December 2017, updated 1st December 2017 · UKMi This updated Medicines Q&A evaluates the available evidence for the different treatment options for hot flushes in men treated for prostate cancer Attachments · Word · 208 KB Regional Medicines (...) Information Manager, London Medicines Information Service · · Copyright © 2019 SPS - Specialist Pharmacy Service. All Rights Reserved.

2017 Specialist Pharmacy Services

20. Large ten-year trial on treatment of localised prostate cancer will aid management decisions

Large ten-year trial on treatment of localised prostate cancer will aid management decisions Large ten-year trial on treatment of localised prostate cancer will aid management decisions Discover Portal Discover Portal Large ten-year trial on treatment of localised prostate cancer will aid management decisions Published on 15 September 2016 doi: New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical surgery or radiotherapy (...) , alongside the fact that many localised cancers (confined to the prostate) may not require detection or treatment. Management of localised prostate cancer is controversial because it’s difficult to predict which cancers will behave aggressively. Most will be slow-growing and unlikely to cause many symptoms or affect life-expectancy. Therefore, radical treatments such as surgery or radiotherapy which can have significant side effects may not be necessary, but adopting a “wait and see” policy risks cancer

2018 NIHR Dissemination Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>